Trade

with

United Therapeutics Corp
(NASDAQ: UTHR)
AdChoices
132.36
+3.58
+2.78%
After Hours :
132.36
0.00
0.00%

Open

130.07

Previous Close

128.78

Volume (Avg)

460.07k (929.49k)

Day's Range

128.76-132.81

52Wk Range

81.60-136.93

Market Cap.

6.26B

Dividend Rate ( Yield )

-

Beta

1.37

Shares Outstanding

47.27M

P/E Ratio (EPS)

25.58 (5.17)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 1.12B

    • Net Income

    • 174.56M

    • Market Cap.

    • 6.26B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 23.41

    • PEG (Price/Earnings Growth) Ratio

    • 0.09

    • Beta

    • 1.37

    • Forward P/E

    • 8.87

    • Price/Sales

    • 6.00

    • Price/Book Value

    • 5.33

    • Price/Cash flow

    • 23.42

      • EBITDA

      • 328.22M

      • Return on Capital %

      • 15.10

      • Return on Equity %

      • 24.09

      • Return on Assets %

      • 15.10

      • Book Value/Share

      • 24.83

      • Shares Outstanding

      • 47.27M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 130.33

        • Credit Rating

        • -

        • Analysts

        • 5

        • EPS Estimate

        • 13.64

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 15.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -42.70

          • 17.04

          • Net Income

            Q/Q (last year)

          • 40.10

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 31.74

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 88.47

            • 82.75

            • Pre-Tax Margin

            • 37.87

            • 39.38

            • Net Profit Margin

            • 23.41

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 87.80

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 28.60

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • 20.20

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 1.34

              • 2.92

              • Quick Ratio

              • 1.18

              • 2.35

              • Interest Coverage

              • 25.69

              • 38.02

              • Leverage Ratio

              • 1.66

              • 2.21

              • Book Value/Share

              • 24.83

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 24.94

                • 217.39

                • P/E Ratio 5-Year High

                • 26.49

                • 634.30

                • P/E Ratio 5-Year Low

                • 7.07

                • 124.82

                • Price/Sales Ratio

                • 5.83

                • 9.52

                • Price/Book Value

                • 5.19

                • 8.61

                • Price/Cash Flow Ratio

                • 23.42

                • 50.51

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • 24.09

                        (17.20)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • 15.10

                        (10.80)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • 20.13

                        (12.10)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • 399.08k

                      • 117.08k

                      • Inventory Turnover

                      • 2.70

                      • 1.48

                      • Asset Turnover

                      • 0.65

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      292.50M
                      Operating Margin
                      26.19
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      23.42
                      Ownership

                      Institutional Ownership

                      -

                      Top 10 Institutions

                      42.46%

                      Mutual Fund Ownership

                      53.04%

                      Float

                      73.91%

                      5% / Insider Ownership

                      0.08%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity® Ser Intrinsic Opportunities Fd

                      •  

                        1,250,000

                      • 13.64

                      • 2.64

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        1,068,109

                      • 0.00

                      • 2.26

                      • BlackRock Capital Appreciation Fund

                      •  

                        884,726

                      • 17.28

                      • 1.87

                      • Vanguard Small Cap Index

                      •  

                        780,028

                      • 3.66

                      • 1.65

                      • Vanguard Total Stock Mkt Idx

                      •  

                        732,013

                      • 4.18

                      • 1.55

                      • iShares Core S&P Mid-Cap (AU)

                      •  

                        647,338

                      • 0.13

                      • 1.37

                      • iShares Nasdaq Biotechnology

                      •  

                        610,768

                      • -0.47

                      • 1.29

                      • Vanguard Small Cap Growth Index Fund

                      •  

                        527,228

                      • 1.63

                      • 1.12

                      • T. Rowe Price Health Sciences Fund

                      •  

                        482,243

                      • -0.29

                      • 1.02

                      • Vanguard Extended Market Index Fund

                      •  

                        433,888

                      • 5.52

                      • 0.92

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity Management and Research Company

                      •  

                        4,491,678

                      • -22.31%

                      • 9.51

                      • Vanguard Group, Inc.

                      •  

                        2,829,053

                      • -5.17%

                      • 5.99

                      • ARONSON+JOHNSON+ORTIZ

                      •  

                        2,060,960

                      • -4.51%

                      • 4.36

                      • BlackRock Fund Advisors

                      •  

                        1,922,189

                      • -3.09%

                      • 4.07

                      • LSV Asset Management

                      •  

                        1,895,328

                      • +8.64%

                      • 4.01

                      • Acadian Asset Management LLC

                      •  

                        1,766,892

                      • -6.11%

                      • 3.74

                      • State Street Corp

                      •  

                        1,383,686

                      • -3.21%

                      • 2.93

                      • TimesSquare Capital Management, LLC

                      •  

                        1,308,900

                      • +94.95%

                      • 2.77

                      • Palo Alto Investors, LLC

                      •  

                        1,213,828

                      • -44.88%

                      • 2.57

                      • BlackRock Advisors LLC

                      •  

                        1,187,031

                      • -27.81%

                      • 2.51

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Aggressive Growth

                      Style

                      Mid Core

                      United Therapeutics Corp was incorporated in Delaware in June 1996. The Company is a biotechnology company, which is focused on the development and commercialization of products to address the medical needs of patients with chronic a...morend life-threatening conditions. The Company operates in two business segments: pharmaceuticals and telemedicine. The pharmaceutical segment includes all activities associated with the research, development, manufacturing and commercialization of its therapeutic products. The telemedicine segment includes all activities associated with the development and manufacturing of patient cardiac monitoring products and services. Its therapeutic products include: Prostacyclin analogues (Remodulin®, Tyvaso®, Orenitram™, 314d, TransCon treprostinil and TransCon beraprost), Phosphodi...moreesterase type 5 (PDE-5) inhibitor (Adcirca®), Monoclonal antibody for oncologic applications, Glycobiology antiviral agents, Cell-based therapy, and Lung transplantation. The Company competes with the developers, manufacturers and distributors of all of these products for customers, funding, access to licenses, personnel, third-party collaborators, product development and commercialization.lessless

                      Key People

                      Martine A. Rothblatt,PhD,M.B.A.,J.D.

                      CEO/Chairman of the Board/Director/Founder

                      Christopher Patusky,J.D.

                      Director/Vice Chairman of the Board

                      John M. Ferrari

                      CFO/Chief Accounting Officer/Treasurer

                      Paul A. Mahon,J.D.

                      Executive VP/General Counsel/Secretary

                      Raymond Dwek,F.R.S.

                      Director

                      • United Therapeutics Corp

                      • 1040 Spring Street

                      • Silver Spring, MD 20910

                      • USA.Map

                      • Phone: +1 301 608-9292

                      • Fax: +1 301 608-9291

                      • unither.com

                      Incorporated

                      1996

                      Employees

                      706

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: